Recent Approvals: Erdafitinib and Enfortumab for Second-Line Treatment of Metastatic Bladder Cancer

ASCO eLearning Podcasts

0:00
05:39
10
10

Recent Approvals: Erdafitinib and Enfortumab for Second-Line Treatment of Metastatic Bladder Cancer

ASCO eLearning Podcasts

Dr. Winston Tan, Medical Oncologist at Mayo Clinic, discusses the recent FDA approval of erdafitinib and enfortumab for second-line treatment of metastatic bladder cancer.

Episodes
Date
Duration
Recommended episodes :

Episode 2: Living Our Values

ASCO eLearning Podcasts

Episode 1: Beginning the Conversation – Social Determinants of Health and Cancer Care

ASCO eLearning Podcasts

CAR T-cells in Pediatric ALL

ASCO eLearning Podcasts

The podcast ASCO eLearning Podcasts has been added to your home screen.

Dr. Winston Tan, Medical Oncologist at Mayo Clinic, discusses the recent FDA approval of erdafitinib and enfortumab for second-line treatment of metastatic bladder cancer.

Subscribe Install Share
ASCO eLearning Podcasts

Thank you for your subscription

For a better experience, also consider installing the application.

Install